OBJECTIVE: Few randomized controlled trials have focused on the optimal management of patients with type 2 diabetes (T2D) during the transition from the inpatient to outpatient setting. This multicenter open-label study explored a discharge strategy based on admission hemoglobin A1c (HbA1c) to guide therapy in general medicine and surgery patients with T2D. METHODS: Patients with HbA1c ≤7% (53 mmol/mol) were discharged on sitagliptin and metformin; patients with HbA1c between 7 and 9% (53-75 mmol/mol) and those >9% (75 mmol/mol) were discharged on sitagliptinmetformin with glargine U-100 at 50% or 80% of the hospital daily dose. The primary outcome was change in HbA1c at 3 and 6 months after discharge. RESULTS: Mean HbA1c on admission for the entire cohort (N = 253) was 8.70 ± 2.3% and decreased to 7.30 ± 1.5% and 7.30 ± 1.7% at 3 and 6 months ( P<.001). Patients with HbA1c <7% went from 6.3 ± 0.5% to 6.3 ± 0.80% and 6.2 ± 1.0% at 3 and 6 months. Patients with HbA1c between 7 and 9% had a reduction from 8.0 ± 0.6% to 7.3 ± 1.1% and 7.3 ± 1.3%, and those with HbA1c >9% from 11.3 ± 1.7% to 8.0 ± 1.8% and 8.0 ± 2.0% at 3 and 6 months after discharge (both P<.001). Clinically significant hypoglycemia (<54 mg/dL) was observed in 4%, 4%, and 7% among patients with a HbA1c <7%, 7 to 9%, and >9%, while a glucose <40 mg/dL was reported in <1% in all groups. CONCLUSION: The proposed HbA1c-based hospital discharge algorithm using a combination of sitagliptin-metformin was safe and significantly improved glycemic control after hospital discharge in general medicine and surgery patients with T2D. ABBREVIATIONS: BG = blood glucose; DPP-4 = dipeptidyl peptidase-4; eGFR = estimated glomerular filtration rate; HbA1c = hemoglobin A1c; T2D = type 2 diabetes.
OBJECTIVE: Few randomized controlled trials have focused on the optimal management of patients with type 2 diabetes (T2D) during the transition from the inpatient to outpatient setting. This multicenter open-label study explored a discharge strategy based on admission hemoglobin A1c (HbA1c) to guide therapy in general medicine and surgery patients with T2D. METHODS:Patients with HbA1c ≤7% (53 mmol/mol) were discharged on sitagliptin and metformin; patients with HbA1c between 7 and 9% (53-75 mmol/mol) and those >9% (75 mmol/mol) were discharged on sitagliptinmetformin with glargine U-100 at 50% or 80% of the hospital daily dose. The primary outcome was change in HbA1c at 3 and 6 months after discharge. RESULTS: Mean HbA1c on admission for the entire cohort (N = 253) was 8.70 ± 2.3% and decreased to 7.30 ± 1.5% and 7.30 ± 1.7% at 3 and 6 months ( P<.001). Patients with HbA1c <7% went from 6.3 ± 0.5% to 6.3 ± 0.80% and 6.2 ± 1.0% at 3 and 6 months. Patients with HbA1c between 7 and 9% had a reduction from 8.0 ± 0.6% to 7.3 ± 1.1% and 7.3 ± 1.3%, and those with HbA1c >9% from 11.3 ± 1.7% to 8.0 ± 1.8% and 8.0 ± 2.0% at 3 and 6 months after discharge (both P<.001). Clinically significant hypoglycemia (<54 mg/dL) was observed in 4%, 4%, and 7% among patients with a HbA1c <7%, 7 to 9%, and >9%, while a glucose <40 mg/dL was reported in <1% in all groups. CONCLUSION: The proposed HbA1c-based hospital discharge algorithm using a combination of sitagliptin-metformin was safe and significantly improved glycemic control after hospital discharge in general medicine and surgery patients with T2D. ABBREVIATIONS: BG = blood glucose; DPP-4 = dipeptidyl peptidase-4; eGFR = estimated glomerular filtration rate; HbA1c = hemoglobin A1c; T2D = type 2 diabetes.
Authors: Alan J Garber; Etie S Moghissi; Edwin D Bransome; Nataniel G Clark; Stephen Clement; Rhoda H Cobin; Anthony P Furnary; Irl B Hirsch; Philip Levy; Robert Roberts; Greet Van den Berghe; Virginia Zamudio Journal: Endocr Pract Date: 2004 Mar-Apr Impact factor: 3.443
Authors: Guillermo E Umpierrez; Richard Hellman; Mary T Korytkowski; Mikhail Kosiborod; Gregory A Maynard; Victor M Montori; Jane J Seley; Greet Van den Berghe Journal: J Clin Endocrinol Metab Date: 2012-01 Impact factor: 5.958
Authors: G De Berardis; A D'Ettorre; G Graziano; G Lucisano; F Pellegrini; S Cammarota; A Citarella; C A Germinario; V Lepore; E Menditto; A Nicolosi; F Vitullo; A Nicolucci Journal: Nutr Metab Cardiovasc Dis Date: 2011-02-17 Impact factor: 4.222
Authors: Guillermo E Umpierrez; Dawn Smiley; Ariel Zisman; Luz M Prieto; Andres Palacio; Miguel Ceron; Alvaro Puig; Roberto Mejia Journal: Diabetes Care Date: 2007-05-18 Impact factor: 19.112
Authors: Boris Draznin; Janice Gilden; Sherita H Golden; Silvio E Inzucchi; David Baldwin; Bruce W Bode; Jeffrey B Boord; Susan S Braithwaite; Enrico Cagliero; Kathleen M Dungan; Mercedes Falciglia; M Kathleen Figaro; Irl B Hirsch; David Klonoff; Mary T Korytkowski; Mikhail Kosiborod; Lillian F Lien; Michelle F Magee; Umesh Masharani; Gregory Maynard; Marie E McDonnell; Eti S Moghissi; Neda Rasouli; Daniel J Rubin; Robert J Rushakoff; Archana R Sadhu; Stanley Schwartz; Jane Jeffrie Seley; Guillermo E Umpierrez; Robert A Vigersky; Cecilia C Low; Deborah J Wexler Journal: Diabetes Care Date: 2013-07 Impact factor: 19.112
Authors: Guillermo E Umpierrez; Dawn Smiley; Sol Jacobs; Limin Peng; Angel Temponi; Patrick Mulligan; Denise Umpierrez; Christopher Newton; Darin Olson; Monica Rizzo Journal: Diabetes Care Date: 2011-01-12 Impact factor: 19.112
Authors: Guillermo E Umpierrez; Roma Gianchandani; Dawn Smiley; Sol Jacobs; David H Wesorick; Christopher Newton; Farnoosh Farrokhi; Limin Peng; David Reyes; Sangeeta Lathkar-Pradhan; Francisco Pasquel Journal: Diabetes Care Date: 2013-07-22 Impact factor: 19.112
Authors: Audrey White; David Bradley; Elizabeth Buschur; Cara Harris; Jacob LaFleur; Michael Pennell; Adam Soliman; Kathleen Wyne; Kathleen Dungan Journal: JMIR Diabetes Date: 2022-07-26